埃索美拉唑是治疗什么病症的药？

Esomeprazole is a new anti-pathogenic agent. The approved indication of esomeprazole (Nexium) is to prevent the recurrence of gastric ulcer and duodenal ulcer in patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs). The approved indications of esomeprazole (Nexium) in Japan include reflux esophagitis and non-erosive reflux disease (NERD). On July 30, 2020, AstraZeneca announced that China’s National Medical Products Administration (NMPA) officially approved Nexium (esomeprazole sodium) injection for the prevention of stress ulcer bleeding in severe patients.

Esomeprazole is the S-isomer of omeprazole, which reduces gastric acid secretion through a specific raking action mechanism and is a specific inhibitor of proton pumps in parietal cells. Site and mechanism of action: Esomeprazole is a weak base, which is concentrated in the high-acid environment of parietal cell acid secretion microtubules and converted into an active form, thereby inhibiting H+/k+-ATP (proton pump) at this site, inhibiting both basic gastric acid secretion and stimulated gastric acid secretion.

Esomeprazole (Nexium) is available in oral and injection forms. For gastric and duodenal ulcers: 20 mg each time, taken once in the morning. The treatment course for duodenal ulcer is usually 2 to 4 weeks, and the treatment course for gastric ulcer is 4 to 8 weeks. For those with refractory ulcers, 20 mg twice a day or 40 mg once a day can be used. Although oral esomeprazole can achieve good clinical results, in some patients, such as patients with dysphagia, vomiting, acute upper gastrointestinal bleeding and patients recovering from major surgery, when used to treat peptic ulcer bleeding, 40 mg can be given intravenously, once every 12 hours, for 3 days. The first dose may be doubled. For patients with severe bleeding, intravenous infusion of 80 mg can be used for the first dose, and then maintained at 8 mg per hour until the bleeding stops.